Eudaimonia Partners’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

Eudaimonia Partners’s Portfolio PRVL Stock Details PRVL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1,800	Closed	-$42K	–	1678
2020 Q4	$42K	Buy	+1,800	New	+$22.8K	0.01%	652

Eudaimonia Partners's PRVL Position: Q1 2021 in Review

Eudaimonia Partners sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q1 2021, closing a stake of 1,800 shares — an estimated $42K sold.

Eudaimonia Partners first reported a position in PRVL in Q4 2020 and held it in 1 quarter. The position peaked at $42K in Q4 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

Eudaimonia Partners reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Eudaimonia Partners sold 1,800 Prevail Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $42K.
Eudaimonia Partners first reported a position in Prevail Therapeutics Inc. Common Stock in Q4 2020 and held it in 1 quarter.
Eudaimonia Partners's Prevail Therapeutics Inc. Common Stock position peaked at $42K in Q4 2020.
0 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q1 2021.

Based on Eudaimonia Partners's 13F filing for Q1 2021, filed 17 May 2021.